Development and validation of an interpretable deep learning framework for Alzheimer’s disease classification

Shangran Qiu(Boston University), Prajakta Joshi(Boston University), Matthew I. Miller(Boston University), Chonghua Xue(Boston University), Xiao Zhou(Boston University), Cody Karjadi(Boston University), Gary H. Chang(Boston University), Anant S. Joshi(Georgia Institute of Technology), Brigid Dwyer(Boston University), Shuhan Zhu(Boston University), Michelle Kaku(Boston University), Yan Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Yazan J. Alderazi(Texas Tech University), Arun Swaminathan(University of Nebraska Medical Center), Sachin Kedar(University of Nebraska Medical Center), Marie Saint‐Hilaire(Boston University), Sanford Auerbach(Boston University), Jing Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), E. Alton Sartor(Boston University), Rhoda Au(Boston University), Vijaya B. Kolachalama(Boston University)
Brain
April 8, 2020
Cited by 471Open Access
Full Text

Abstract

Alzheimer's disease is the primary cause of dementia worldwide, with an increasing morbidity burden that may outstrip diagnosis and management capacity as the population ages. Current methods integrate patient history, neuropsychological testing and MRI to identify likely cases, yet effective practices remain variably applied and lacking in sensitivity and specificity. Here we report an interpretable deep learning strategy that delineates unique Alzheimer's disease signatures from multimodal inputs of MRI, age, gender, and Mini-Mental State Examination score. Our framework linked a fully convolutional network, which constructs high resolution maps of disease probability from local brain structure to a multilayer perceptron and generates precise, intuitive visualization of individual Alzheimer's disease risk en route to accurate diagnosis. The model was trained using clinically diagnosed Alzheimer's disease and cognitively normal subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset (n = 417) and validated on three independent cohorts: the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) (n = 382), the Framingham Heart Study (n = 102), and the National Alzheimer's Coordinating Center (NACC) (n = 582). Performance of the model that used the multimodal inputs was consistent across datasets, with mean area under curve values of 0.996, 0.974, 0.876 and 0.954 for the ADNI study, AIBL, Framingham Heart Study and NACC datasets, respectively. Moreover, our approach exceeded the diagnostic performance of a multi-institutional team of practicing neurologists (n = 11), and high-risk cerebral regions predicted by the model closely tracked post-mortem histopathological findings. This framework provides a clinically adaptable strategy for using routinely available imaging techniques such as MRI to generate nuanced neuroimaging signatures for Alzheimer's disease diagnosis, as well as a generalizable approach for linking deep learning to pathophysiological processes in human disease.


Related Papers

No related papers found

Powered by citation graph analysis